| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3999650 | Urologic Oncology: Seminars and Original Investigations | 2015 | 5 Pages |
Abstract
The use of neoadjuvant docetaxel chemotherapy in patients with locally advanced PCa undergoing RP remains undefined. Results from this study are informative but only hypothesis generating given the study was not powered for survival. Mature data from the ongoing CALGB 90203 and GETUG-12 studies will shed light on this clinical question.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Bo M.D., Ph.D., Nitin K. M.D., Tianming M.S., Robert M.D., M.S., Eric A. M.D.,